الفهرس 
DiscussionOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
The 1eukocyte adherence inhibition (LAX) test was
app1ied to detect ce11-mediated immunoreactivity re1ated
to human urinary b1adder carcinoma. Pre1iminary resu1ts
- .. •·
showed nonspecific toxic effect of high ca1f serum (CS)
concentrations, thus CS was e1iminated from incubation
medium.
Fo11owing incubation of periphera1 b1ood 1eukocytes
(PBL) from contro1 subjects in protein-free medium,
or medium containing extracts from either urinary b1adder
transitiona1 ce11 carcinoma (TCC) or squamous ce11
carcinoma (SqCC) 1 percentage adherent ce11s was estimated
and considered as contro1 1eve1 of adherence.
A1though tumor extracts were prepared.by one and
the same method, different tumor-antigen preparations
varied vast1y in their abi1ity to give specific adherence
inhibition. Some preparations (SqCC 1 1 TCC 1 and TCC 2)
consistent1y gave a high tumor-specific LAX (20~ decreased
adherence), whi1 another preparation (SqCC 2) did
not. Therefor extracts must be screened for activity in
the LAX test before being used for investigating ce11-
mediated immunity (CMX) of cancer patients.
Since the previous extracts were not enough, adequate
vo1umes were prepared from urinary b1adder squamous
ce11 carcinoma (SqCC 3) 1 transitiona1 ce11 carcinoma
(TCC 3) 1 adenocarcinoma (AdC) and poo1ed contro1 PBL
68
(HL-A). AdC and HL-A (histocompatibi1ity) were used as
contro1 antigens. The nontoxic concentration of extracts
was found to be ~ 150 pg/m1 in case of SqCC 3 1 TCC 3 and
~ -- A~C and ~ 250 ~g/m1 in case of HL-A extracts.
PBL from ~ out of ~ TCC patients showed specific
LAI when reacted with TCC 3 extract, whi1 no reactivity
was observed when they were reacted with SqCC 3 1 AdC and
HL-A extracts. This specific reactivity indicates the
pr~sence of tissue-type specific antigen’s’ (TTSA) in
TCC 3 extract. Simi1ar resu1ts were obtained when PBL
from 6 out of 6 SqCC patients reacted specifica11y with
SqCC 3 extract but not with TCC 3 1 AdC and HL-A extracts.
Thus SqCC 3 extraet is characterised by the presence of
TTSA. No cross-reactivity was observed between the two
types of urinary b1adder carcinoma. This indicates antigenic
differences between these two tumor types of the
same site but of different ce11 types.
LAI responce was confirmed to be stage-dependent
phenomenon. PBL from 7 out of8 SqCC patients (stage 11
·or III disease) showed specific reactivity with SqCC 3
antigenic extract and non with TCC 3 1 AdC and HL-A extracts.
On the other hand on1y 1 out of 13 PBL samp1es derived
from sqec patients (stage IV) showed specific reactivity
with SqCC 3 reactive antigenic extract. LAI was thus
high in patients carrying ear1y-stage neop1asm~ut not
with large tumor burden.
Within one month of surgical removal of stage II
’
or III SqCC, 10 out of 10 SqCC pa~ients showed sp~cific - - reactivity with SqCC 3 antigenic extract. Thus specific
LAI was still retained by patients’ PBL.
It seems thus that the use of the LAI test in
monitoring patients with urinary bladder carcinoma is
warranted.